This led to the development of bevacizumab, a monoclonal antibody against the VEGF-A ligand that binds to KDR. 36KDR status and its relationship with outcomes have been investigated in GBM.20,37–39 However, these studies were performed in a heterogeneous group of patients (IDH-WT and IDH-mutant), prior to the TMZ era, or in relatively small cohorts (Supplementary Table S2). This evidence concerns the gene VEGFA and glioblastoma.